# Zopiclone
*Source: https://go.drugbank.com/drugs/DB01198*

## Overview

### Description

This compound belongs to the class of organic compounds known as cyclopyrrolones. These are compounds belonging to a family of pyridin-2-ylpyrrole based chemicals. The pyrrole is usually fused to a benzene, pyrimidine, or dithiin.

### Background

Zopiclone is a novel hypnotic agent used in the treatment of insomnia. Its mechanism of action is based on modulating benzodiazepine receptors. In addition to zopiclone's benzodiazepine pharmacological properties it also has some barbiturate-like properties.

### Indication

For the short-term treatment of insomnia.

### Pharmacodynamics

Zopiclone is a nonbenzodiazepine hypnotic from the pyrazolopyrimidine class and is indicated for the short-term treatment of insomnia. While Zopiclone is a hypnotic agent with a chemical structure unrelated to benzodiazepines, barbiturates, or other drugs with known hypnotic properties, it interacts with the gamma-aminobutyric acid-benzodiazepine (GABA
B
Z) receptor complex. Subunit modulation of the GABA
B
Z receptor chloride channel macromolecular complex is hypothesized to be responsible for some of the pharmacological properties of benzodiazepines, which include sedative, anxiolytic, muscle relaxant, and anticonvulsive effects in animal models. Zopiclone binds selectively to the brain alpha subunit of the GABA A omega-1 receptor.

### Mechanism of Action

Gamma-aminobutyric acid receptor subunit alpha-1
Potentiator
Gamma-aminobutyric acid receptor subunit alpha-2
Potentiator
Gamma-aminobutyric acid receptor subunit alpha-3
Potentiator
+ 1 more target

### Absorption

Rapidly absorbed following oral administration.

### Metabolism

Extensively metabolized in the liver via decarboxylation (major pathway), demethylation, and side chain oxidation. Metabolites include an N-oxide derivative (weakly active; approximately 12% of a dose) and an N-desmethyl metabolite (inactive; approximately 16%). Approximately 50% of a dose is converted to other inactive metabolites via decarboxylation. Hepatic microsomal enzymes are apparently not involved in zopiclone clearance.
Hover over products below to view reaction partners
Zopiclone
Zopiclone N-oxide
Carbon dioxide
zopiclone-N-oxide
N-desmethylzopiclone

### Half-life

Elimination half life is approximately 5 hours (range 3.8 to 6.5 hours) and is prolonged to 11.9 hours in patients with hepatic insufficiency.

### Toxicity

Rare individual instances of fatal outcomes following overdose with racemic zopiclone have been reported in European postmarketing reports, most often associated with overdose with other CNS-depressant agent. Signs and symptoms of overdose effects of CNS depressants can be expected to present as exaggerations of the pharmacological effects noted in preclinical testing.

### Drug Interactions

This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.

1,2-Benzodiazepine
The risk or severity of adverse effects can be increased when 1,2-Benzodiazepine is combined with Zopiclone.
Abametapir
The serum concentration of Zopiclone can be increased when it is combined with Abametapir.
Abatacept
The metabolism of Zopiclone can be increased when combined with Abatacept.
Abiraterone
The metabolism of Zopiclone can be decreased when combined with Abiraterone.
Abrocitinib
The metabolism of Abrocitinib can be decreased when combined with Zopiclone.

### Food Interactions

Avoid alcohol. Ingesting alcohol may potentiate the CNS depressant actions of zopiclone.
Avoid grapefruit products. Grapefruit may reduce the CYP3A4 metabolism of zopiclone, increasing its sedative effects.

## Chemical Information

**DrugBank ID:** DB01198

**Synonyms:** (+-)-zopiclone
(±)-zopiclone
6-(5-Chloro-2-pyridinyl)-7-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyrazin-5-yl 4-methyl-1-piperazinecarboxylate
Zopiclona
Zopiclone
Zopiclonum

**Chemical Formula:** C
17
H
17
ClN
6
O
3

**SMILES:** CN1CCN(CC1)C(=O)OC1N(C(=O)C2=NC=CN=C12)C1=NC=C(Cl)C=C1

**Weight:** Average: 388.808
Monoisotopic: 388.105066147

**IUPAC Name:** 6-(5-chloropyridin-2-yl)-7-oxo-5H,6H,7H-pyrrolo[3,4-b]pyrazin-5-yl 4-methylpiperazine-1-carboxylate

## Additional Information

### Modality

Small Molecule

### Patents

0

### Indicated Conditions

1

### Phase 0

1

### Phase 1

12

### Phase 2

1

### Phase 3

9

### Phase 4

4

### Therapeutic Categories

Hypnotics
(Nonbenzodiazepine)
Miscellaneous Anxiolytics Sedatives and
Hypnotics

### Summary

Zopiclone
is a nonbenzodiazepine hypnotic used for the short-term management of insomnia.

### Brand Names

Imovane

### Generic Name

Zopiclone

### DrugBank Accession Number

DB01198

### Groups

Approved, Investigational

### Structure

3D
Download
MOL
SDF
3D-SDF
PDB
SMILES
InChI
Similar Structures
Structure for Zopiclone (DB01198)
×
Close

### External IDs

RP 27267
RP-27267

### Associated Conditions

Indication Type
Indication
Combined Product Details
Approval Level
Age Group
Patient Characteristics
Dose Form
Treatment of
Insomnia
••••••••••••
Create Account
Create Account

### Mechanism of action

Zopiclone exerts its action by binding on the benzodiazepine receptor complex and modulation of the GABA
B
Z receptor chloride channel macromolecular complex. Both zopiclone and benzodiazepines act indiscriminately at the benzodiazepine binding site on α1, α2, α3 and α5 GABAA containing receptors as full agonists causing an enhancement of the inhibitory actions of GABA to produce the therapeutic (hypnotic and anxiolytic) and adverse effects of zopiclone.
Target
Actions
Organism
A
Gamma-aminobutyric acid receptor subunit alpha-1
potentiator
Humans
A
Gamma-aminobutyric acid receptor subunit alpha-2
potentiator
Humans
A
Gamma-aminobutyric acid receptor subunit alpha-3
potentiator
Humans
A
Gamma-aminobutyric acid receptor subunit alpha-5
potentiator
Humans
U
Translocator protein
agonist
Humans

### Protein binding

Approximately 45%

### International/Other Brands

Amoban
/
Zimovane

### Brand Name Prescription Products

Name
Dosage
Strength
Route
Labeller
Marketing Start
Marketing End
Region
Image
Act Zopiclone
Tablet
5 mg
Oral
Teva Italia S.R.L.
2005-11-11
2025-06-24
Canada
Act Zopiclone
Tablet
7.5 mg
Oral
Teva Italia S.R.L.
2005-11-11
2025-06-24
Canada
Imovane
Tablet
5.0 mg
Oral
Sanofi Aventis Deutschland Gmb H
1998-02-10
2022-05-24
Canada
Imovane
Tablet
7.5 mg
Oral
Sanofi Aventis Deutschland Gmb H
1990-12-31
Not applicable
Canada
M-zopiclone
Tablet
7.5 mg
Oral
Mantra Pharma Inc
2018-04-16
Not applicable
Canada

### Generic Prescription Products

Name
Dosage
Strength
Route
Labeller
Marketing Start
Marketing End
Region
Image
Ag-zopiclone
Tablet
5 mg
Oral
Angita Pharma Inc.
2018-07-25
Not applicable
Canada
Ag-zopiclone
Tablet
3.75 mg
Oral
Angita Pharma Inc.
2018-12-21
Not applicable
Canada
Ag-zopiclone
Tablet
7.5 mg
Oral
Angita Pharma Inc.
2018-07-25
Not applicable
Canada
Apo-zopiclone
Tablet
7.5 mg
Oral
Apotex Corporation
1996-09-19
Not applicable
Canada
Apo-zopiclone
Tablet
5 mg
Oral
Apotex Corporation
2002-06-04
Not applicable
Canada

### ATC Codes

N05CF01 — Zopiclone
N05CF — Benzodiazepine related drugs
N05C — HYPNOTICS AND SEDATIVES
N05 — PSYCHOLEPTICS
N — NERVOUS SYSTEM

### Drug Categories

Aza Compounds
Benzodiazepine hypnotics and sedatives
Central Nervous System Agents
Central Nervous System Depressants
Cytochrome P-450 CYP2C8 Substrates
Cytochrome P-450 CYP2C9 Substrates
Cytochrome P-450 CYP3A Substrates
Cytochrome P-450 CYP3A4 Substrates
Cytochrome P-450 Substrates
Drugs causing inadvertant photosensitivity
Hypnotics (Nonbenzodiazepine)
Hypnotics and Sedatives
Methemoglobinemia Associated Agents
Miscellaneous Anxiolytics Sedatives and Hypnotics
Nervous System
Photosensitizing Agents
Psycholeptics
Sleep Initiation and Maintenance Disorders
Zopiclone and prodrugs

### Chemical TaxonomyProvided byClassyfire

Description
This compound belongs to the class of organic compounds known as cyclopyrrolones. These are compounds belonging to a family of pyridin-2-ylpyrrole based chemicals. The pyrrole is usually fused to a benzene, pyrimidine, or dithiin.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Pyrrolopyrazines
Sub Class
Cyclopyrrolones
Direct Parent
Cyclopyrrolones
Alternative Parents
Piperazine carboxylic acids
/
2-heteroaryl carboxamides
/
N-methylpiperazines
/
Pyridines and derivatives
/
Pyrazines
/
Aryl chlorides
/
Imidolactams
/
Tertiary carboxylic acid amides
/
Carbamate esters
/
Heteroaromatic compounds
/
Trialkylamines
/
Organic carbonic acids and derivatives
/
Lactams
/
Azacyclic compounds
/
Carbonyl compounds
/
Hydrocarbon derivatives
/
Organic oxides
/
Organochlorides
/
Organopnictogen compounds
show 9 more
Substituents
1,4-diazinane
/
2-heteroaryl carboxamide
/
Amine
/
Amino acid or derivatives
/
Aromatic heteropolycyclic compound
/
Aryl chloride
/
Aryl halide
/
Azacycle
/
Carbamic acid ester
/
Carbonic acid derivative
/
Carbonyl group
/
Carboxamide group
/
Carboxylic acid derivative
/
Cyclopyrrolone
/
Heteroaromatic compound
/
Hydrocarbon derivative
/
Imidolactam
/
Lactam
/
N-alkylpiperazine
/
N-methylpiperazine
/
Organic nitrogen compound
/
Organic oxide
/
Organic oxygen compound
/
Organochloride
/
Organohalogen compound
/
Organonitrogen compound
/
Organooxygen compound
/
Organopnictogen compound
/
Piperazine
/
Piperazine-1-carboxylic acid
/
Pyrazine
/
Pyridine
/
Tertiary aliphatic amine
/
Tertiary amine
/
Tertiary carboxylic acid amide
show 25 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
pyrrolopyrazine, monochloropyridine (
CHEBI:32315
)

### Kingdom

Organic compounds

### Super Class

Organoheterocyclic compounds

### Class

Pyrrolopyrazines

### Sub Class

Cyclopyrrolones

### Direct Parent

Cyclopyrrolones

### Alternative Parents

Piperazine carboxylic acids
/
2-heteroaryl carboxamides
/
N-methylpiperazines
/
Pyridines and derivatives
/
Pyrazines
/
Aryl chlorides
/
Imidolactams
/
Tertiary carboxylic acid amides
/
Carbamate esters
/
Heteroaromatic compounds
/
Trialkylamines
/
Organic carbonic acids and derivatives
/
Lactams
/
Azacyclic compounds
/
Carbonyl compounds
/
Hydrocarbon derivatives
/
Organic oxides
/
Organochlorides
/
Organopnictogen compounds
show 9 more

### Substituents

1,4-diazinane
/
2-heteroaryl carboxamide
/
Amine
/
Amino acid or derivatives
/
Aromatic heteropolycyclic compound
/
Aryl chloride
/
Aryl halide
/
Azacycle
/
Carbamic acid ester
/
Carbonic acid derivative
/
Carbonyl group
/
Carboxamide group
/
Carboxylic acid derivative
/
Cyclopyrrolone
/
Heteroaromatic compound
/
Hydrocarbon derivative
/
Imidolactam
/
Lactam
/
N-alkylpiperazine
/
N-methylpiperazine
/
Organic nitrogen compound
/
Organic oxide
/
Organic oxygen compound
/
Organochloride
/
Organohalogen compound
/
Organonitrogen compound
/
Organooxygen compound
/
Organopnictogen compound
/
Piperazine
/
Piperazine-1-carboxylic acid
/
Pyrazine
/
Pyridine
/
Tertiary aliphatic amine
/
Tertiary amine
/
Tertiary carboxylic acid amide
show 25 more

### Molecular Framework

Aromatic heteropolycyclic compounds

### External Descriptors

pyrrolopyrazine, monochloropyridine (
CHEBI:32315
)

### Affected organisms

Humans and other mammals

### UNII

03A5ORL08Q

### CAS number

43200-80-2

### InChI Key

GBBSUAFBMRNDJC-UHFFFAOYSA-N

### InChI

InChI=1S/C17H17ClN6O3/c1-22-6-8-23(9-7-22)17(26)27-16-14-13(19-4-5-20-14)15(25)24(16)12-3-2-11(18)10-21-12/h2-5,10,16H,6-9H2,1H3

### Synthesis Reference

Thomas Jerussi, "Compositions comprising zopiclone derivatives and methods of making and using the same." U.S. Patent US20040147521, issued July 29, 2004.
US20040147521

### General References

Liu HJ, Sato K, Shih HC, Shibuya T, Kawamoto H, Kitagawa H: Pharmacologic studies of the central action of zopiclone: effects on locomotor activity and brain monoamines in rats. Int J Clin Pharmacol Ther Toxicol. 1985 Mar;23(3):121-8. [
Article
]
Sato K, Hong YL, Yang MS, Shibuya T, Kawamoto H, Kitagawa H: Pharmacologic studies of central actions of zopiclone: influence on brain monoamines in rats under stressful condition. Int J Clin Pharmacol Ther Toxicol. 1985 Apr;23(4):204-10. [
Article
]
Dundar Y, Dodd S, Strobl J, Boland A, Dickson R, Walley T: Comparative efficacy of newer hypnotic drugs for the short-term management of insomnia: a systematic review and meta-analysis. Hum Psychopharmacol. 2004 Jul;19(5):305-22. [
Article
]
Blanchard JC, Julou L: Suriclone: a new cyclopyrrolone derivative recognizing receptors labeled by benzodiazepines in rat hippocampus and cerebellum. J Neurochem. 1983 Mar;40(3):601-7. [
Article
]
Julou L, Bardone MC, Blanchard JC, Garret C, Stutzmann JM: Pharmacological studies on zopiclone. Pharmacology. 1983;27 Suppl 2:46-58. [
Article
]

### External Links

Human Metabolome Database
HMDB0015329
KEGG Drug
D01372
PubChem Compound
5735
PubChem Substance
46505233
ChemSpider
5533
BindingDB
50248251
RxNav
40001
ChEBI
32315
ChEMBL
CHEMBL135400
Therapeutic Targets Database
DAP000427
PharmGKB
PA10236
Drugs.com
Drugs.com Drug Page
Wikipedia
Zopiclone

### Human Metabolome Database

HMDB0015329

### KEGG Drug

D01372

### PubChem Compound

5735

### PubChem Substance

46505233

### ChemSpider

5533

### BindingDB

50248251

### RxNav

40001

### ChEBI

32315

### ChEMBL

CHEMBL135400

### Therapeutic Targets Database

DAP000427

### PharmGKB

PA10236

### Drugs.com

Drugs.com Drug Page

### Wikipedia

Zopiclone

### Packagers

Centaur Pharmaceuticals Pvt Ltd.

### Dosage Forms

Form
Route
Strength
Tablet
Oral
Tablet
Oral
5 mg
Tablet
Oral
7.5 mg
Tablet
Oral
5.0 mg
Tablet
Oral
7.500 mg
Tablet, film coated
Oral
7.5 MG
Tablet
Oral
3.75 mg
Tablet, coated
Oral
Tablet, film coated
Oral
3.75 MG
Tablet, film coated
Oral
5 mg
Tablet, coated
Oral
7.5 mg
Tablet, coated
Oral
750000 mg
Tablet, film coated
Oral

### Prices

Unit description
Cost
Unit
Imovane 7.5 mg Tablet
1.41USD
tablet
Imovane 5 mg Tablet
1.11USD
tablet
Apo-Zopiclone 7.5 mg Tablet
0.49USD
tablet
Co Zopiclone 7.5 mg Tablet
0.49USD
tablet
Mylan-Zopiclone 7.5 mg Tablet
0.49USD
tablet
Novo-Zopiclone 7.5 mg Tablet
0.49USD
tablet
Nu-Zopiclone 7.5 mg Tablet
0.49USD
tablet
Pms-Zopiclone 7.5 mg Tablet
0.49USD
tablet
Ran-Zopiclone 7.5 mg Tablet
0.49USD
tablet
Ratio-Zopiclone 7.5 mg Tablet
0.49USD
tablet
Rhovane 7.5 mg Tablet
0.49USD
tablet
Sandoz Zopiclone 7.5 mg Tablet
0.49USD
tablet
Zopiclone 7.5 mg Tablet
0.49USD
tablet
Apo-Zopiclone 5 mg Tablet
0.23USD
tablet
Co Zopiclone 5 mg Tablet
0.23USD
tablet
Mylan-Zopiclone 5 mg Tablet
0.23USD
tablet
Novo-Zopiclone 5 mg Tablet
0.23USD
tablet
Pms-Zopiclone 5 mg Tablet
0.23USD
tablet
Ran-Zopiclone 5 mg Tablet
0.23USD
tablet
Ratio-Zopiclone 5 mg Tablet
0.23USD
tablet
Sandoz Zopiclone 5 mg Tablet
0.23USD
tablet
Zopiclone 5 mg Tablet
0.23USD
tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.

### State

Solid

### Experimental Properties

Property
Value
Source
melting point (°C)
178 °C
PhysProp
water solubility
0.151 mg/mL at 25 °C
MEYLAN,WM et al. (1996)
logP
0.8
Not Available

### Predicted Properties

Property
Value
Source
Water Solubility
0.885 mg/mL
ALOGPS
logP
0.97
ALOGPS
logP
0.52
Chemaxon
logS
-2.6
ALOGPS
pKa (Strongest Acidic)
8.04
Chemaxon
pKa (Strongest Basic)
6.86
Chemaxon
Physiological Charge
0
Chemaxon
Hydrogen Acceptor Count
6
Chemaxon
Hydrogen Donor Count
0
Chemaxon
Polar Surface Area
91.76 Å
2
Chemaxon
Rotatable Bond Count
3
Chemaxon
Refractivity
95.89 m
3
·mol
-1
Chemaxon
Polarizability
38.22 Å
3
Chemaxon
Number of Rings
4
Chemaxon
Bioavailability
1
Chemaxon
Rule of Five
Yes
Chemaxon
Ghose Filter
Yes
Chemaxon
Veber's Rule
No
Chemaxon
MDDR-like Rule
No
Chemaxon

### Predicted ADMET Features

Property
Value
Probability
Human Intestinal Absorption
+
1.0
Blood Brain Barrier
+
0.9382
Caco-2 permeable
+
0.5805
P-glycoprotein substrate
Substrate
0.6917
P-glycoprotein inhibitor I
Inhibitor
0.6381
P-glycoprotein inhibitor II
Inhibitor
0.5
Renal organic cation transporter
Non-inhibitor
0.6785
CYP450 2C9 substrate
Non-substrate
0.7158
CYP450 2D6 substrate
Non-substrate
0.9115
CYP450 3A4 substrate
Substrate
0.6775
CYP450 1A2 substrate
Non-inhibitor
0.9046
CYP450 2C9 inhibitor
Non-inhibitor
0.9071
CYP450 2D6 inhibitor
Non-inhibitor
0.923
CYP450 2C19 inhibitor
Inhibitor
0.8995
CYP450 3A4 inhibitor
Non-inhibitor
0.8309
CYP450 inhibitory promiscuity
Low CYP Inhibitory Promiscuity
0.689
Ames test
AMES toxic
0.5332
Carcinogenicity
Non-carcinogens
0.9174
Biodegradation
Not ready biodegradable
0.9941
Rat acute toxicity
2.6411 LD50, mol/kg
Not applicable
hERG inhibition (predictor I)
Weak inhibitor
0.7838
hERG inhibition (predictor II)
Non-inhibitor
0.5688
ADMET data is predicted using
admetSAR
, a free tool for evaluating chemical ADMET properties. (
23092397
)

### Spectra

Spectrum
Spectrum Type
Splash Key
Predicted GC-MS Spectrum - GC-MS
Predicted GC-MS
splash10-05bb-9212000000-b3e4c2874ff86d2544e1
Mass Spectrum (Electron Ionization)
MS
splash10-0007-6950000000-c1583a92e3cbc5066186
LC-MS/MS Spectrum - LC-ESI-QTOF , positive
LC-MS/MS
splash10-00kb-0090000000-9d80e08080f406848221
LC-MS/MS Spectrum - LC-ESI-QFT , positive
LC-MS/MS
splash10-0002-0092000000-977d45f9a516242be80f
LC-MS/MS Spectrum - LC-ESI-QFT , positive
LC-MS/MS
splash10-0002-0090000000-397a508c11f66c161327
LC-MS/MS Spectrum - LC-ESI-QFT , positive
LC-MS/MS
splash10-014j-0090000000-abc6a676659114a83d08
LC-MS/MS Spectrum - LC-ESI-QFT , positive
LC-MS/MS
splash10-014i-0790000000-74d7c73e854e61700433
LC-MS/MS Spectrum - LC-ESI-QFT , positive
LC-MS/MS
splash10-00lr-0920000000-2c17f6282d1031cb4d50
LC-MS/MS Spectrum - LC-ESI-QFT , positive
LC-MS/MS
splash10-001i-0900000000-c0f92aba9374337ff737
LC-MS/MS Spectrum - LC-ESI-QFT , positive
LC-MS/MS
splash10-003r-5900000000-46755df8b5cfb7f46bf9
LC-MS/MS Spectrum - LC-ESI-QFT , positive
LC-MS/MS
splash10-004i-9300000000-091d5434bc674d5bf9a4
LC-MS/MS Spectrum - LC-ESI-QFT , positive
LC-MS/MS
splash10-004i-9000000000-87365fa01fb0854897ca
Predicted MS/MS Spectrum - 10V, Positive (Annotated)
Predicted LC-MS/MS
splash10-000i-0009000000-ecc43b453bcef84eb6dd
Predicted MS/MS Spectrum - 10V, Negative (Annotated)
Predicted LC-MS/MS
splash10-000i-0019000000-856593370c65f718fda8
Predicted MS/MS Spectrum - 20V, Positive (Annotated)
Predicted LC-MS/MS
splash10-000i-0019000000-1e8ff416debdbb051176
Predicted MS/MS Spectrum - 20V, Negative (Annotated)
Predicted LC-MS/MS
splash10-056a-0394000000-3169034c01e3fd5ad2c9
Predicted MS/MS Spectrum - 40V, Positive (Annotated)
Predicted LC-MS/MS
splash10-001i-1945000000-a1bb6829667ca9894ef3
Predicted MS/MS Spectrum - 40V, Negative (Annotated)
Predicted LC-MS/MS
splash10-0019-9621000000-be3e21df1b3a2d39364c
13C NMR Spectrum
1D NMR
Not Applicable
Predicted 1H NMR Spectrum
1D NMR
Not Applicable
Predicted 13C NMR Spectrum
1D NMR
Not Applicable

### Chromatographic Properties

Collision Cross Sections (CCS)
Adduct
CCS Value (Å
2
)
Source type
Source
[M-H]-
198.1988232
predicted
DarkChem Lite v0.1.0
[M-H]-
185.05937
predicted
DeepCCS 1.0 (2019)
[M+H]+
199.0918232
predicted
DarkChem Lite v0.1.0
[M+H]+
187.57133
predicted
DeepCCS 1.0 (2019)
[M+Na]+
198.7405232
predicted
DarkChem Lite v0.1.0
[M+Na]+
194.7325
predicted
DeepCCS 1.0 (2019)

### Kind

Protein

### Organism

Humans

### Pharmacological action

Unknown

### Actions

Substrate

### General Function

Dual cyclooxygenase and peroxidase that plays an important role in the biosynthesis pathway of prostanoids, a class of C20 oxylipins mainly derived from arachidonate ((5Z,8Z,11Z,14Z)-eicosatetraenoate, AA, C20:4(n-6)), with a particular role in the inflammatory response. The cyclooxygenase activity oxygenates AA to the hydroperoxy endoperoxide prostaglandin G2 (PGG2), and the peroxidase activity reduces PGG2 to the hydroxy endoperoxide prostaglandin H2 (PGH2), the precursor of all 2-series prostaglandins and thromboxanes. This complex transformation is initiated by abstraction of hydrogen at carbon 13 (with S-stereochemistry), followed by insertion of molecular O2 to form the endoperoxide bridge between carbon 9 and 11 that defines prostaglandins. The insertion of a second molecule of O2 (bis-oxygenase activity) yields a hydroperoxy group in PGG2 that is then reduced to PGH2 by two electrons (PubMed:7947975). Involved in the constitutive production of prostanoids in particular in the stomach and platelets. In gastric epithelial cells, it is a key step in the generation of prostaglandins, such as prostaglandin E2 (PGE2), which plays an important role in cytoprotection. In platelets, it is involved in the generation of thromboxane A2 (TXA2), which promotes platelet activation and aggregation, vasoconstriction and proliferation of vascular smooth muscle cells (Probable). Can also use linoleate (LA, (9Z,12Z)-octadecadienoate, C18:2(n-6)) as substrate and produce hydroxyoctadecadienoates (HODEs) in a regio- and stereospecific manner, being (9R)-HODE ((9R)-hydroxy-(10E,12Z)-octadecadienoate) and (13S)-HODE ((13S)-hydroxy-(9Z,11E)-octadecadienoate) its major products (By similarity)

### Specific Function

heme binding

### Gene Name

PTGS1

### Uniprot ID

P23219

### Uniprot Name

Prostaglandin G/H synthase 1

### Molecular Weight

68685.82 Da

### Curator comments

This is a potential target based on the benzodiazepine drug-class mechanism, however, direct evidence is not readily available in the literature.

